Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid
Rating agencies Moody's and S&P assigned investment-grade ratings to Sun Pharmaceutical Industries. This action follows Sun Pharma's proposed acquisition of US-based Organon & Co. The deal is expected to significantly bolster Sun Pharma's business position and revenue base. Organon will contribute substantially to the group's earnings after the acquisition. This…
The Economic Times ·